🧬 50 Pearls — NPM1-Mutated AML & Co-Mutational Risk (HARMONY Study) (Based on the Leukemia 2026 HARMONY analysis) 1️⃣ NPM1 mutation occurs in ~30% of adult AML and defines the largest AML molecular subtype. 2️⃣ Prognosis is generally favorable but strongly influenced by co-mutations. 3️⃣ Historically, FLT3-ITD was the only co-mutation included in risk stratification. 4️⃣ The ELN-2022 system classifies NPM1-mut AML mainly by FLT3-ITD presence. 5️⃣ The HARMONY database analyzed 1,763 intensively treated adult NPM1-mut AML patients. 6️⃣ The training cohort included 1001 patients from AMLSG and HOVON trials. 7️⃣ Median age was ~53 years. 8️⃣ Normal karyotype occurs in ~80–88% of NPM1-mut AML. 9️⃣ Composite CR rate ~87% after induction. 🔟 Allo-HSCT performed in ~34% of patients. ⸻ 🔬 Co-Mutation Landscape 1️⃣1️⃣ Most frequent mutations: FLT3 (54%), DNMT3A (53%). 1️⃣2️⃣ Other frequent genes: NRAS, PTPN11, TET2, IDH1/2. 1️⃣3️⃣ FLT3-ITD present in ~39% of cases. 1️⃣4️⃣ DNMT3A mutations often co-occur with FLT3-ITD. 1️⃣5️⃣ 59.5% of FLT3-ITD cases also carry DNMT3A mutations. 1️⃣6️⃣ Triple mutation NPM1 + FLT3-ITD + DNMT3A is common (~23%). 1️⃣7️⃣ This triple-mutated group has very poor prognosis. 1️⃣8️⃣ Median RFS in triple mutation AML <9 months. 1️⃣9️⃣ IDH mutations may modulate prognosis depending on context. 2️⃣0️⃣ IDH mutations may paradoxically improve outcomes in some FLT3-ITD subsets. ⸻ 🧬 Clonal Evolution 2️⃣1️⃣ Early mutations: DNMT3A, TET2, IDH1/2. 2️⃣2️⃣ NPM1 mutations occur later in leukemogenesis. 2️⃣3️⃣ RAS pathway mutations tend to occur late in disease evolution. 2️⃣4️⃣ Early epigenetic mutations may create a pre-leukemic stem cell state. 2️⃣5️⃣ NPM1-mut AML may contain up to 13 gene mutations per patient. ⸻ 🧪 HARMONY Risk Classification 2️⃣6️⃣ The model integrates FLT3-ITD, DNMT3A, IDH1/2, TET2. 2️⃣7️⃣ Patients stratified into 3 risk groups. 2️⃣8️⃣ Favorable: 51.8% of patients. 2️⃣9️⃣ Intermediate: 24.8%. 3️⃣0️⃣ Adverse: 23.4%. 3️⃣1️⃣ Median OS favorable group ~14.4 years. 3️⃣2️⃣ Median OS intermediate group ~2.2 years. 3️⃣3️⃣ Median OS adverse group ~0.9 years. 3️⃣4️⃣ CR rate highest in favorable group (~91%). 3️⃣5️⃣ RFS not reached in favorable subgroup. ⸻ 🔄 Impact vs ELN Classification 3️⃣6️⃣ The HARMONY model reclassified ~42.7% of NPM1-mut AML patients. 3️⃣7️⃣ Many ELN favorable cases shifted to intermediate risk. 3️⃣8️⃣ Some intermediate patients moved to adverse category. 3️⃣9️⃣ Predictive accuracy improved vs ELN-2022 (AUC 0.695 vs 0.635). 4️⃣0️⃣ Demonstrates importance of co-mutational patterns. ⸻ 🩺 Transplant Implications 4️⃣1️⃣ Allo-HSCT in CR1 benefits most the adverse subgroup. 4️⃣2️⃣ Limited benefit of HSCT in favorable subgroup. 4️⃣3️⃣ Intermediate group shows moderate transplant benefit. 4️⃣4️⃣ HSCT hazard ratio improvement strongest in adverse group. ⸻ 🧪 Other Genomic Insights 4️⃣5️⃣ TP53 mutations remain rare but highly adverse. 4️⃣6️⃣ RUNX1 mutations associated with worse outcomes. 4️⃣7️⃣ SRSF2 mutations show intermediate prognosis. 4️⃣8️⃣ STAG2 mutations may correlate with favorable outcomes. 4️⃣9️⃣ Adverse cytogenetics are uncommon in NPM1-mut AML. 5️⃣0️⃣ Combining baseline genomics + MRD will likely define future AML risk models. ⸻ 🧬 Take-Home: NPM1-mut AML prognosis is not uniform — co-mutational architecture (FLT3-ITD, DNMT3A, IDH, TET2) significantly refines risk and may guide allo-HSCT decisions. ⸻ #AML #NPM1 #Hematology #Leukemia #PrecisionMedicine #MyeloidNeoplasms #HemOnc #ASH #ELN2022 #MolecularHematology